<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Continuous glucose monitoring: an Endocrine Society clinical practice guideline.&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Klonoff DC, Buckingham B, Christiansen JS, Montori VM, Tamborlane WV, Vigersky RA, Wolpert H, Endocrine Society. Continuous glucose monitoring: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2011 Oct;96(10):2968-79. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21976745&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Diabetes with other coma, type I [juvenile type], not stated as uncontrolled  (250.31); Diabetes with other coma, type II or unspecified type, not stated as uncontrolled  (250.30)"/><FieldValue Value="MSH: Diabetes Mellitus ; Diabetes Mellitus, Type 1 ; Diabetes Mellitus, Type 2 ; Intensive Care Units ; Monitoring, Intraoperative ; Operating Rooms ; Patient Education as Topic "/><FieldValue Value="MTH: Diabetes Mellitus ; Diabetes Mellitus, Insulin-Dependent ; Diabetes Mellitus, Non-Insulin-Dependent ; Hemoglobin A1c measurement ; intensive care unit ; Operating Room ; Patient education (procedure) "/><FieldValue Value="SNOMEDCT_US: Ambulatory continuous glucose monitoring of interstitial tissue fluid  (439926003); Diabetes mellitus  (73211009); Hemoglobin A1c measurement  (43396009); Intensive care unit  (309904001); Operating theatre  (225738002); Patient education  (311401005); Type 1 diabetes mellitus  (46635009); Type 2 diabetes mellitus  (44054006)"/><FieldValue Value="UMD: Monitors, Personal, Glucose, Implantable Sensor  (20-185)"/></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Type 1 diabetes mellitus (T1DM) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Type 2 diabetes mellitus (T2DM) &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Assessment of Therapeutic Effectiveness" /><FieldValue Value="Management" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Endocrinology" /><FieldValue Value="Family Practice" /><FieldValue Value="Internal Medicine" /><FieldValue Value="Pediatrics" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Advanced Practice Nurses" /><FieldValue Value="Nurses" /><FieldValue Value="Physician Assistants" /><FieldValue Value="Physicians" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;To formulate practice guidelines for determining settings where patients are most likely to benefit from the use of continuous glucose monitoring (CGM), specifically:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Real-time CGM in adult hospital settings &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Real-time CGM in children and adolescent outpatients &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Real-time CGM in adult outpatients &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Adult and pediatric patients with type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM)&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Real-time continuous glucose monitoring (RT-CGM) alone for glucose management in adults in the intensive care unit or the operating room (considered but recommended against) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;RT-CGM based on hemoglobin A1c (HbA1c) levels &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Provision of treatment guidelines to patients &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Intermittent use of CGM systems in selected adult and pediatric patients &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;RT-CGM for children under 8 years of age (considered but no recommendations made for or against) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Hemoglobin A1C (HbA1C) levels &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Time hyperglycemic or hypoglycemic &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Incidence of severe hyperglycemia and hypoglycemia &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Incidence of nocturnal hypoglycemia &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Emergency medical service utilization for extremes of glycemia &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Accuracy of glucose monitoring devices &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Efficacy and safety of continuous glucose monitoring (CGM) devices versus self-monitoring blood glucose (SMBG) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patient satisfaction and feasibility &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Quality of life &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Eligibility Criteria&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Task Force included randomized controlled trials (RCTs) of adults and children with type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM) in the outpatient setting. Literature search did not discriminate between different types of continuous glucose monitoring (CGM); both real-time and non-real-time CGM devices were included. The control groups needed to utilize self-monitored blood glucose (SMBG). The Task Force included RCTs regardless of their publication status, language, size, or primary objective. The Task Force excluded trials that did not have sufficient follow-up (8 weeks), were conducted in inpatient settings, had different methods of insulin delivery between the intervention and comparison arms, and primarily studied pregnant subjects.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Study Identification&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;An expert reference librarian designed and conducted the electronic search strategy with input from study investigators with expertise in conducting systematic reviews. To identify eligible studies, the Task Force searched electronic databases (MEDLINE, EMBASE, Cochrane CENTRAL, Web of Science, and Scopus) from 1996 to November 15, 2010. A combination of medical subject headings and text words were utilized. The detailed search strategy is available from the corresponding author of the original guideline document.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Assessment of Study Eligibility&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Pairs of reviewers independently screened all abstracts and titles and selected potentially eligible studies for full-text assessment. The process was repeated in duplicate for full-text review. Disagreements were resolved by consensus or arbitration. Kappa for study selection was 0.80.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Search Results&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;See Table 1 and Table 2 and discussion in the companion document (see the &quot;Availability of Companion Documents&quot; field) for information on the characteristics and methodological quality of the 19 trials that enrolled 1,801 patients.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A total of 990 references were screened as abstracts and 150 of them were deemed potentially eligible. Full-text review of these 150 references resulted in exclusion of 131 references (18 were not original research reports, 113 were nonrandomized). 19 studies were included.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Expert Consensus" /><FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Quality of the Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;+OOO&lt;/strong&gt; Denotes very low quality evidence&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;++OO&lt;/strong&gt; Denotes low quality evidence&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;+++O&lt;/strong&gt; Denotes moderate quality evidence&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;++++&lt;/strong&gt; Denotes high quality evidence&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Meta-Analysis" /><FieldValue Value="Review of Published Meta-Analyses" /><FieldValue Value="Systematic Review with Evidence Tables" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;To synthesize evidence, the Task Force undertook a systematic review and meta-analysis of randomized controlled trials (RCTs) to evaluate the efficacy and safety of continuous glucose monitoring (CGM) compared to self-monitored blood glucose (SMBG) with regards to improving glycemic control and reducing hypoglycemia in both adult and pediatric populations with type 1 and type 2 diabetes mellitus (T1DM and T2DM).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Data Collection&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Working in duplicate, a standardized form was used to extract data on study characteristics: description of participants, age, gender, number of patients involved, type of CGM, duration and frequency of use, and type of SMBG used. The Task Force also extracted outcomes of interest: hemoglobin A1c (HbA1c), time hyperglycemic and hypoglycemic, incidence of severe hyperglycemia and hypoglycemia, incidence of nocturnal hypoglycemia, emergency medical service utilization for extremes of glycemia, and patient satisfaction of CGM. Reviewers also appraised the methodological quality of eligible RCTs, considering adequacy of allocation concealment, blinding of patients, health care providers, data collectors and outcome assessors, if an RCT was stopped early, and the extent of loss to follow-up (i.e., proportion of patients in whom the investigators were unable to ascertain outcomes). For each of these variables, the Task Force used results reported in the original RCTs, thus accepting the authors' definitions of these terms. When needed, the Task Force contacted authors of the studies included by email to obtain missing data or confirm extracted data.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Statistical Analysis&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Task Force estimated the effect of CGM from each study with 95% confidence interval (CI) using the weighted mean difference (WMD) for continuous outcomes and the relative risk (RR) for dichotomous outcomes. The former measure retains the original data units and the latter is a unitless ratio. An event rate ratio was estimated if a study reported hypoglycemic and hyperglycemic events per period of time. The estimates from each study were pooled using a random-effects model incorporating the between-study heterogeneity as well as the within-study heterogeneity. The extent of heterogeneity was assessed using the I&lt;sup&gt;2&lt;/sup&gt; statistic. Interaction between subgroups was tested using an interaction test and meta-regression. A priori established subgroup analyses were based on the type of CGM (real-time versus non-real-time), loss to follow up, and adherence monitoring. To assess publication bias, the Task Force planned to inspect funnel plots visually and test their symmetry statistically using Egger's regression test.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The Clinical Guidelines Subcommittee of The Endocrine Society deemed&amp;nbsp;continuous glucose monitoring (CGM) a priority area in need of practice guidelines and appointed a Task Force to formulate evidence-based recommendations.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Participants&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Endocrine Society appointed a Task Force of experts, a methodologist, and a medical writer.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Task Force followed the approach recommended by the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) workgroup, an international group with expertise in development and implementation of evidence-based guidelines. A detailed description of the grading scheme has been published elsewhere.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Task Force used the best available research evidence that Task Force members identified and one commissioned systematic literature review of randomized controlled trials of CGM use to inform some of the recommendations. The Task Force also used consistent language and graphical descriptions of both the strength of a recommendation and the quality of evidence. In terms of the strength of the recommendation, strong recommendations use the phrase &quot;the Task Force recommends&quot; and the number 1, and weak recommendations use the phrase &quot;the Task Force suggests&quot; and the number 2. The symbol +OOO denotes very low quality evidence; ++OO, low quality; +++O, moderate quality; and ++++, high quality. The Task Force has confidence that persons who receive care according to the strong recommendations will derive, on average, more good than harm. Weak recommendations require more careful consideration of the person's circumstances, values, and preferences to determine the best course of action. Linked to each recommendation is a description of the evidence and the values that panelists considered in making the recommendation. All of the Task Force's recommendations are expert opinions and are evidence based. Some of these opinions are based on stronger evidence than others. For strong recommendations with GRADE 1 evidence, the Task Force has made recommendations, and for weak recommendations with GRADE 2 evidence, the Task Force has made suggestions.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Consensus Process&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;One group meeting, several conference calls, and e-mail communications enabled consensus.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Strength of Recommendation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;1&lt;/strong&gt;- Indicates a strong recommendation and is associated with the phrase &quot;The Task Force recommends.&quot;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;2&lt;/strong&gt; - Denotes a weak recommendation and is associated with the phrase &quot;The Task Force suggests.&quot;&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The Task Force has considered the cost-benefit issues related to the use of continuous glucose monitoring (CGM) and feels that the clinical benefits justify the costs in a wide range of patients, but that these values may not be universally shared in some healthcare settings (e.g., those with resource-constrained settings, clinics unable to provide adequate support to patients and families). Individuals or health systems may disagree with the Task Force's relative valuation, and in these cases the recommendations may not apply. It may then be necessary to modify these recommendations accordingly.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="External Peer Review" /><FieldValue Value="Internal Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Committees and members of The Endocrine Society, the Diabetes Technology Society, and the European Society of Endocrinology reviewed and commented on preliminary drafts of these guidelines.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Definitions for the quality of the evidence (+OOO, ++OO, +++O, and ++++); the strength of the recommendation (1 or 2); and the difference between a &quot;recommendation&quot; and a &quot;suggestion&quot; are provided at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Real-Time Continuous Glucose Monitoring (RT-CGM) in Adult Hospital Settings&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Task Force recommends against the use of RT-CGM alone for glucose management in the intensive care unit (ICU) or operating room until further studies provide sufficient evidence for its accuracy and safety in those settings (1 | +OOO).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;RT-CGM in Children and Adolescent Outpatients&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Task Force recommends that RT-CGM with currently approved devices be used by children and adolescents with type 1 diabetes mellitus (T1DM) who have achieved glycosylated hemoglobin (HbA1c) levels below 7.0% because it will assist in maintaining target HbA1c levels while limiting the risk of hypoglycemia (1 | ++++).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Task Force recommends RT-CGM devices be used with children and adolescents with T1DM who have HbA1c levels of at least 7.0% who are able to use these devices on a nearly daily basis (1 | +++O).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Task Force makes no recommendations for or against the use of RT-CGM by children with T1DM who are less than 8 yr of age.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Task Force suggests that treatment guidelines be provided to patients to allow them to safely and effectively take advantage of the information provided to them by RT-CGM (2 | +OOO).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Task Force suggests the intermittent use of CGM systems designed for short-term retrospective analysis in pediatric patients with diabetes in whom clinicians worry about nocturnal hypoglycemia, dawn phenomenon, and postprandial hyperglycemia; in patients with hypoglycemic unawareness; and in patients experimenting with important changes to their diabetes regimen (such as instituting new insulin or switching from multiple daily injections [MDI] to pump therapy) (2 | +OOO).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;RT-CGM in Adult Outpatients&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Task Force recommends that RT-CGM devices be used by adult patients with T1DM who have HbA1c levels of at least 7.0% and who have demonstrated that they can use these devices on a nearly daily basis (1 | ++++).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Task Force recommends that RT-CGM devices be used by adult patients with T1DM who have HbA1c levels less than 7.0% and who have demonstrated that they can use these devices on a nearly daily basis (1 | ++++).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Task Force suggests that intermittent use of CGM systems designed for short-term retrospective analysis may be of benefit in adult patients with diabetes to detect nocturnal hypoglycemia, the dawn phenomenon, and postprandial hyperglycemia, and to assist in the management of hypoglycemic unawareness and when significant changes are made to their diabetes regimen (such as instituting new insulins or switching from MDI to pump therapy) (2 | +OOO).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Definitions&lt;/span&gt;&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Quality of the Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;+OOO&lt;/strong&gt; Denotes very low quality evidence&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;++OO&lt;/strong&gt; Denotes low quality evidence&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;+++O&lt;/strong&gt; Denotes moderate quality evidence&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;++++&lt;/strong&gt; Denotes high quality evidence&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Strength of Recommendation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;1&lt;/strong&gt; - Indicates a strong recommendation and is associated with the phrase &quot;The Task Force recommends.&quot;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;2&lt;/strong&gt; - Denotes a weak recommendation and is associated with the phrase &quot;The Task Force suggests.&quot;&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None provided&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of evidence supporting the recommendations is specifically stated for each recommendations (see the &quot;Major Recommendations&quot; field).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Appropriate use of continuous glucose monitoring in pediatric and adult patients to improve glycemic control&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;No significant adverse effects related to the device were reported in any of the trials. Data on the incidence of severe hypoglycemia, hyperglycemia, nocturnal hypoglycemia, or severe hyperglycemia were very sparse, poorly reported, and imprecise. The relative risk (RR) for hypoglycemia (based on number of patients suffering at least one episode of hypoglycemia as the unit of analysis) was 1.02 (95% CI, 0.3 to 3.45). Using the number of events as the unit of analysis, the rate ratio for hypoglycemia was 3.50 (95% CI, 1.07 to 11.44) and for hyperglycemia 1.42 (95% CI, 0.26 to 7.82).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="432" OrdBy="900" Name="Qualifying Statements"><Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Clinical Practice Guidelines are developed to be of assistance to endocrinologists and other health care professionals by providing guidance and recommendations for particular areas of practice. The Guidelines should not be considered inclusive of all proper approaches or methods, or exclusive of others. The Guidelines cannot guarantee any specific outcome, nor do they establish a standard of care. The Guidelines are not intended to dictate the treatment of a particular patient. Treatment decisions must be made based on the independent judgment of health care providers and each patient's individual circumstances. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The Endocrine Society makes no warranty, express or implied, regarding the Guidelines and specifically excludes any warranties of merchantability and fitness for a particular use or purpose. The Society shall not be liable for direct, indirect, special, incidental, or consequential damages related to the use of the information contained herein. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;An implementation strategy was not provided.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="117" OrdBy="1015" ID="437" Name="Implementation Tools" Type="picklist-many"><FieldValue Value="Patient Resources" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Living with Illness" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /><FieldValue Value="Patient-centeredness" /><FieldValue Value="Safety" /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Klonoff DC, Buckingham B, Christiansen JS, Montori VM, Tamborlane WV, Vigersky RA, Wolpert H, Endocrine Society. Continuous glucose monitoring: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2011 Oct;96(10):2968-79. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21976745&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="2011 Oct" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="The Endocrine Society - Professional Association" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The Endocrine Society&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Continuous Glucose Monitoring Task Force&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Task Force Members&lt;/em&gt;: David C. Klonoff (&lt;em&gt;Chair&lt;/em&gt;); Bruce Buckingham; Jens S . Christiansen; Victor M. Montori; William V. Tamborlane; Robert A. Vigersky; and Howard Wolpert&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Financial Disclosures of the Task Force&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;David C. Klonoff, M.D., F.A.C.P. (chair)&lt;/strong&gt; &amp;mdash; Financial or Business/Organizational Interests: Bayer, C8 MediSensors, Insuline, LifeScan, Medtronic Diabetes, Roche; Significant Financial Interest or Leadership Position: Diabetes Technology Society&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Bruce Buckingham, M.D.&lt;/strong&gt; &amp;mdash; Financial or Business/Organizational Interests: MedTronic MiniMed, LifeScan, Novo Nordisk, JDRF, UnoMedical; Significant Financial Interest or Leadership Position: none declared&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Jens S. Christiansen, M.D., F.R.C.P.I., Dr.Med.Sci.&lt;/strong&gt; &amp;mdash; Financial or Business/Organizational Interests: Novo Nordisk, Roche; Significant Financial Interest or Leadership Position: European Society of Endocrinology&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Victor M. Montori, M.D.&lt;/strong&gt;* &amp;mdash; Financial or Business/Organizational Interests: KER Unit (Mayo Clinic); Significant Financial Interest or Leadership Position: none declared&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;William V. Tamborlane, M.D.&lt;/strong&gt; &amp;mdash; Financial or Business/Organizational Interests: Medtronic Diabetes, Abbott Diabetes, Novo Nordisk, Eli Lilly, Macrogenics; Significant Financial Interest or Leadership Position: Novo Nordisk, Eli Lilly, Medtronic, Macrogenics&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Robert A. Vigersky, M.D.&lt;/strong&gt; &amp;mdash; Financial or Business/Organizational Interests: Dexcom; Significant Financial Interest or Leadership Position: The Endocrine Society&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Howard Wolpert, M.D.&lt;/strong&gt; &amp;mdash; Financial or Business/Organizational Interests: Insulet, Novo Nordisk, Roche; Significant Financial Interest or Leadership Position: Insulet&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;*Evidence-based reviews for this guideline were prepared under contract with The Endocrine Society.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="159" OrdBy="1255" ID="453" Name="Guideline Endorser(s)" Type="orglist"><FieldValue Value="Diabetes Technology Society - Disease Specific Society" /><FieldValue Value="European Society of Endocrinology - Medical Specialty Society" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: Available in Portable Document Format (PDF) from &lt;a href=&quot;https://www.endocrine.org/~/media/endosociety/Files/Publications/Clinical%20Practice%20Guidelines/FINAL-Standalone-Color-CGM-Guideline.pdf&quot; title=&quot;The Endocrine Society Web site&quot;&gt;The Endocrine Society Web site&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Print copies: Available from The Endocrine Society, Phone: (301) 941.0210; Email: &lt;a href=&quot;mailto:Societyservices@endo-society.org&quot;&gt;Societyservices@endo-society.org&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following is available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Gandhi GY, Kovalaske M, Kudva Y, Walsh K, Elamin MB, Beers M, Coyle C, Goalen M, Murad MS, Erwin PJ, Corpus J, Montori VM, Murad MH. Efficacy of continuous glucose monitoring in improving glycemic control and reducing hypoglycemia: a systematic review and meta-analysis of randomized trials. J Diabetes Sci Technol. 5(4):952-965. Electronic copies: Available to subscribers from the &lt;a href=&quot;http://journalofdst.org/worldpress/2011/09/06/efficacy-of-continuous-glucose-monitoring-in-improving-glycemic-control-and-reducing-hypoglycemia-a-systematic-review-and-meta-analysis-of-randomized-trials/&quot; title=&quot;Journal of Diabetes Science and Technology Web site&quot;&gt;Journal of Diabetes Science and Technology Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following is available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Patient guide to continuous glucose monitoring. Chevy Chase (MD): The Hormone Foundation; 2011 Oct. 2 p. Electronic copies: Available from &lt;a href=&quot;http://www.hormone.org/patient-guides/2011/continuous-glucose-monitoring&quot; title=&quot;The Hormone Foundation Web site&quot;&gt;The Hormone Foundation Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Print copies: Available from The Endocrine Society, Phone: (301) 941.0210; Email: &lt;a href=&quot;mailto:Societyservices@endo-society.org&quot;&gt;Societyservices@endo-society.org&lt;/a&gt;&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Disclaimer&quot;&gt;Please note: This patient information is intended to provide health professionals with information to share with their patients to help them better understand their health and their diagnosed disorders. By providing access to this patient information, it is not the intention of NGC to provide specific medical advice for particular patients. Rather we urge patients and their representatives to review this material and then to consult with a licensed health professional for evaluation of treatment options suitable for them as well as for diagnosis and answers to their personal medical questions. This patient information has been derived and prepared from a guideline for health care professionals included on NGC by the authors or publishers of that original guideline. The patient information is not reviewed by NGC to establish whether or not it accurately reflects the original guideline's content.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI Institute on June 12, 2012. The information was verified by the guideline developer on June 22, 2012.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is an author manuscript copyrighted by The Endocrine Society. This may not be duplicated or reproduced, other than for personal use or within the rule of &quot;Fair Use of Copyrighted Materials&quot; (section 107, Title 17, U.S. Code) without permission of the copyright owner, The Endocrine Society. From the time of acceptance following peer review, the full text of this manuscript is made freely available by The Endocrine Society at &lt;a href=&quot;http://www.endo-society.org/guidelines/Current-Clinical-Practice-Guidelines.cfm&quot; title=&quot;The Endocrine Society Web site&quot;&gt;http://www.endo-society.org/guidelines/Current-Clinical-Practice-Guidelines.cfm&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
